159 related articles for article (PubMed ID: 16680756)
1. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
Ozdemir E; Koc Y; Kansu E
Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
[No Abstract] [Full Text] [Related]
2. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Lazarevic V; Golovleva I; Nygren I; Wahlin A
Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
[No Abstract] [Full Text] [Related]
3. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Kiguchi T; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
[TBL] [Abstract][Full Text] [Related]
4. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
5. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
7. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
Carella AM; Lerma E
Ann Hematol; 2007 Oct; 86(10):749-52. PubMed ID: 17576558
[TBL] [Abstract][Full Text] [Related]
8. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
Breccia M; Stagno F; Vigneri P; Latagliata R; Cannella L; Del Fabro V; Di Raimondo F; Alimena G
Am J Hematol; 2010 May; 85(5):375-7. PubMed ID: 20306543
[No Abstract] [Full Text] [Related]
9. What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
Ruiz-Argüelles GJ
Haematologica; 2002 Mar; 87(3):ELT15. PubMed ID: 11869961
[No Abstract] [Full Text] [Related]
10. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
11. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
12. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
13. Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
Tefferi A
Cancer; 2011 Jan; 117(2):234-7. PubMed ID: 21210471
[No Abstract] [Full Text] [Related]
14. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia.
Miyachi K; Ihara A; Hankins RW; Murai R; Maehiro S; Miyashita H
Clin Rheumatol; 2003 Oct; 22(4-5):329-32. PubMed ID: 14576993
[TBL] [Abstract][Full Text] [Related]
15. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Mahon FX; Molimard M
Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
[No Abstract] [Full Text] [Related]
16. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
18. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
[TBL] [Abstract][Full Text] [Related]
19. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
Yokote T; Akioka T; Nakayama S; Oka S; Hara S; Yamano T; Tsuji M; Hanafusa T
Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
[TBL] [Abstract][Full Text] [Related]
20. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
